Enveda raises $311 million to accelerate AI-driven drug discovery

Artificial intelligence is increasingly expanding its reach beyond traditional technology fields, now making inroads into cutting-edge pharmaceutical research. Enveda, a US company specializing in drug discovery based on natural compounds, has announced a massive $311 million funding round, giving it a valuation of $2 billion, according to TechCrunch.

A hybrid approach: nature and algorithms

Enveda's strategy rests on an unusual combination: it uses molecules found in nature as a starting point, then analyzes and optimizes them using AI models specifically trained for pharmaceutical chemistry. The idea behind this method is that nature has already been "experimenting" with complex molecular structures for millions of years, and AI can significantly speed up the process of identifying the most promising candidates for treatment.

In theory, this approach reduces the time and costs associated with the early stages of drug development—a process that traditionally takes years and requires enormous investment before a compound even reaches the clinical testing phase.

What treatments the company is developing

Enveda is currently testing several drug candidates in clinical trials, including some aimed at skin conditions. Another major area of focus is helping patients maintain the results achieved with GLP-1 agonist treatments, which have become hugely popular for weight loss. The company is developing solutions designed to prevent weight regain after patients stop taking these medications—a problem frequently reported by both patients and doctors.

A signal for the biotech industry

The $2 billion valuation places Enveda among the fastest-growing AI-biotech startups of recent years. The funding round confirms investors' appetite for companies that manage to transform laboratory research—traditionally slow and costly—into an accelerated process powered by the computing and analytical capabilities of modern algorithms.